摘要
目的:探究紫杉醇脂质体、紫杉醇分别联合卡铂在卵巢癌中的疗效与安全性。方法:选取2018年12月-2019年6月本院收治的上皮性卵巢癌患者80例为研究对象,根据治疗方式的不同将其分为对照组(紫杉醇联合卡铂组)和观察组(紫杉醇脂质体联合卡铂组),每组40例。比较两组的临床疗效、不良反应发生率及生存质量评分。结果:治疗6个疗程后,两组的临床疗效比较,差异无统计学意义(P>0.05);观察组恶心呕吐、白细胞下降、中性粒细胞减少、神经毒性、血红蛋白下降的发生率均低于对照组,差异均有统计学意义(P<0.05);治疗后观察组的生存质量各维度评分均显著高于对照组,差异均有统计学意义(P<0.05)。结论:紫杉醇脂质体、紫杉醇分别联合卡铂在卵巢癌中的疗效无明显差异,但紫杉醇脂质体联合卡铂的不良反应发生率相对较低,因此在本类患者中的应用价值更高。
Objective:To investigate the efficacy and safety of Paclitaxel Liposome and Paclitaxel combined with Carboplatin in ovarian cancer.Method:A total of 80 cases of epithelial ovarian cancer admitted to our hospital from December 2018 to June 2019 were selected as the study objects.They were divided into control group (Paclitaxel combined with Carboplatin group) and observation group (Paclitaxel Liposome combined with Carboplatin group) according to different treatment methods,40 cases in each group.The clinical efficacy,incidence of adverse reactions and quality of life scores of the two groups were compared.Result:After six sessions of treatment,comparison of clinical efficacy between the two groups,the difference was not statistically significant (P>0.05).The incidence of nausea and vomiting,decreased white blood cells,neutropenia,neurotoxicity and decreased hemoglobin in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).The scores of all dimensions of life quality in the observation group after treatment were significantly higher than those in the control group,the differences were statistically significant (P<0.05).Conclusion:There is no significant difference in the efficacy of Paclitaxel Liposome and Paclitaxel combined with Carboplatin in ovarian cancer,but the incidence of adverse reactions of Paclitaxel Liposome combined with Carboplatin is relatively low,so the application value in this class of patients is higher.
作者
叶泳珊
陈济煜
林燕玲
温东瑜
卢健淳
雷晓妹
YE Yongshan;CHEN Jiyu;LIN Yanling;WEN Dongyu;LU Jianchun;LEI Xiaomei(The People’s Hospital of Jiangmen,Jiangmen 529000,China)
出处
《中国医学创新》
CAS
2020年第6期129-133,共5页
Medical Innovation of China
基金
江门市科技计划项目(2019020400170002892)。
关键词
紫杉醇脂质体
紫杉醇
卡铂
卵巢癌
安全性
Paclitaxel Liposome
Paclitaxel
Carboplatin
Ovarian cancer
Safety